Previous 10 | Next 10 |
Marinus Pharmaceuticals (NASDAQ: MRNS ) +39% on positive ganaloxone data . More news on: Marinus Pharmaceuticals, Inc., Pieris Pharmaceuticals, Inc., SAExploration Holdings, Inc., Stocks on the move, Read more ...
Noteworthy events during the week of September 22 - 28 for healthcare investors. More news on: UroGen Pharma Ltd., Medtronic plc, ENDRA Life Sciences Inc., Healthcare stocks news, , Read more ...
There is no worse tyranny than to force a man to pay for what he does not want merely because you think it would be good for him ." - Robert A. Heinlein, The Moon is a Harsh Mistress Today, we revisit Pieris Pharmaceuticals ( PIRS ) as we have not looked in on this intriguing ' Tier 4 '...
The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with this Read more ...
Pieris Pharmaceuticals (NASDAQ: PIRS ) appoints Hitto Kaufmann, Ph.D. as Senior Vice President and Chief Scientific Officer. More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
BOSTON, MA / ACCESSWIRE / September 3 , 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today annou...
BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indicatio...
Pieris Pharmaceuticals, Inc. (PIRS) Q2 2019 Results Conference Call August 1, 2019 8:00 AM ET Company Participants Allan Reine – Chief Financial Officer Steve Yoder – President and Chief Executive Officer Lou Matis – Senior Vice President and Chief Developmen...
Company to Host an Investor Conference Call on Thursday, August 1, 2019 at 8:00 AM EDT BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through ...
BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, to...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
18.14%Change Percent:
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 millio...